AGM 2020

Aug 19, 2020

Good afternoon. I'm Pete Salzman, Chief Executive Officer and the Director of Immunovant. I'm very happy to welcome you to the Immunovant twenty twenty Stockholders Meeting. Before I call the meeting to order, I'd like to introduce you to the other members of the Board and the executive leadership team who are joining me virtually today. The other members of the Board on the call include Frank Torty, our Board Chairperson as well as Doug Hughes, George Mogowski, Atul Pandey, and Eric Banker. The executive officers of Immunovant here today are Pam Keneally, our chief financial officer Julia Butchko, our chief development and technology officer and Brad Mittelkopf, our general counsel and secretary. Also present are Tony Torrington and Joel Wagner from Ernst and Young LLP, ImmunoVance auditor. I will be acting as chairperson of this meeting. Brad Mittelkoff will act as secretary of this meeting. The meeting will now officially come to order. We will proceed with the formal business of the meeting as set forth in your notice of annual meeting and proxy statement. After the formal meeting, we will give you an opportunity to ask questions. Will the secretary please report at this time with respect to the mailing of the notice of the meeting and the stockholders list? Brad, we don't hear you. Is someone from Broadridge able to activate Brad's line? This is the conference operator. Mister Middlecoff's line is open. Not sure if he if he lost connections, but I'm seeing that he's still here. Okay. We'll give him a moment to join us. He must have lost his connection. Any of those from medical office reconnected. Okay. He's reconnecting. Thank you. Hi. Sorry. I got got dropped there somehow. Great. So moving forward, whether yeah. Will the secretary please report at this time with respect to the mailing of the notice of the meeting and the stockholders' list? Yes. I have at this meeting a complete list of the stockholders of record of Immunovant's common stock on 06/22/2020, the record date for this meeting. I also have an affidavit certifying that on 07/09/2020, a notice of annual meeting of stockholders of Immunovant was deposited in The United States mail to stockholders of record at the close of business on 06/22/2020. Thank you, Brad. At this time, I'd like to introduce Gary Wozniak of Broadridge, who I'm appointing to act as inspector of election at this meeting. Mister Wozniak has taken and subscribed the customary oath of office to execute his duties with strict impartiality. We will file this oath with the records of the meeting. His function is to decide upon the qualifications of voters, accept their votes, and when balloting on all matters is completed, to tally the final votes. Will the secretary please report at this time with respect to the existence of a quorum? Thanks. I've been informed by the inspector of election that proxies have been received for approximately 84% of the aggregate voting power of the outstanding shares of common stock entitled to vote at this meeting. This constitutes a quorum for the meeting today, and we may now carry out the official business of the meeting. We will now proceed with the formal business of this meeting. There are two proposals to be considered by the stockholders at this meeting. The time is now 01:05PM eastern time on Wednesday, August 19, and the polls are now open for voting on all matters to be presented. The polls will be closed to voting after we go through the matters to be voted on. The agenda and rules of conduct for the meeting are posted on the annual meeting portal. We ask that you follow these rules to help the meeting run smoothly. We will address questions during the q and a portion of the meeting. If you have a question, please submit it by entering it into the ask a question text box on the bottom right hand corner of the annual meeting portal. The first item of business is the election of three directors to serve until the twenty twenty one annual meeting and until their successors are elected. The nominees for director are Andrew Cromkin, George Mogowski and Peter Salzman. The second item of business today is the ratification of the selection by the audit committee of our board of directors of Ernst and Young LLP as the independent registered public accounting firm of Immunovant for the fiscal year ending 03/31/2021. That was the final proposal for today's meeting. The secretary will now describe the voting procedures. Thanks, Pete. If you've already voted, there is no need to vote now unless you would like to change your vote. If you have not voted and you would like to vote now or if you would like to change your vote, click the vote here button at the bottom right hand corner of the annual meeting portal. We will pause for a moment to give anyone who hasn't yet voted a chance to vote. Each share of common stock is entitled to one vote. The time is now 01:07PM eastern time, and the polls are now closed for voting. The report of the inspector of election covering the proposals presented at this meeting is as follows. Number one, the proposal to elect each of Andrew Fromkin, George Mengalski, and Peter Salzman as a director is carried. Number two, the selection of Ernst and Young LLP as our independent registered public accounting firm for the fiscal year ended 03/31/2021 is ratified. We expect to report our final voting results in a current form on form eight k to be filed with the SEC within four business days after the end of this meeting. This concludes the formal portion of today's meeting. We will now entertain questions from stockholders. There being no questions, the meeting is now adjourned. Thank you everyone.